Prof. Dr. med. Peter Fasching

Professur für Translationale Frauenheilkunde und Geburtshilfe

Evaluation of automated techniques for extraction of circulating cell-free DNA for implementation in standardized high-throughput workflows (2023) Lehle S, Emons J, Hack C, Heindl F, Hein A, Preuß C, Seitz K, et al. Journal article RANK Expression as an Independent Predictor for Response to Neoadjuvant Chemotherapy in Luminal-Like Breast Cancer: A Translational Insight from the GeparX Trial (2023) Link T, Blohmer JU, Schmitt WD, Kuhlmann JD, Just M, Untch M, Stoetzer OJ, et al. Journal article Improving the Quality of Care for Cancer Patients through Oncological Second Opinions in a Comprehensive Cancer Center: Feasibility of Patient-Initiated Second Opinions through a Health-Insurance Service Point (2023) Schulmeyer C, Beckmann M, Fasching P, Häberle L, Golcher H, Kunath F, Wullich B, Emons J Journal article Quality of Life and Treatment-Related Side Effects in Patients With HR+/HER2- Advanced Breast Cancer: Findings From a Multicountry Survey (2023) Cardoso F, Rihani J, Harmer V, Harbeck N, Casas A, Rugo HS, Fasching P, et al. Journal article Effects of an App-Based Mindfulness Intervention during Pregnancy on the Infant’s Prenatal Androgen Exposure: A Randomized Controlled Pilot Trial (2023) Siegmann EM, Eichler A, Buchholz VN, Gerlach J, Pontones C, Titzmann A, Arnaud N, et al. Journal article Clinical Characteristics and Prognosis of HER2-0 and HER2-Low-Positive Breast Cancer Patients: Real-World Data from Patients Treated with Neoadjuvant Chemotherapy (2023) Pöschke P, Fasching P, Adler W, Rübner M, Beckmann M, Hack C, Heindl F, et al. Journal article Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial (2023) Williams TM, Schneeweiss A, Jackisch C, Shen C, Weber KE, Fasching P, Denkert C, et al. Journal article Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study (2023) Hurvitz SA, Bardia A, Quiroga V, Park YH, Blancas I, Alonso-Romero JL, Vasiliev A, et al. Journal article A genome-wide gene-environment interaction study of breast cancer risk for women of European ancestry (2023) Middha P, Wang X, Behrens S, Bolla MK, Wang Q, Dennis J, Michailidou K, et al. Journal article Evaluating the Effectiveness of Mobile Health in Breast Cancer Care: A Systematic Review (2023) Flaucher M, Zakreuskaya A, Nissen M, Mocker A, Fasching P, Beckmann M, Eskofier B, Leutheuser H Journal article, Review article